Instructions: The Enrollment Form should be completed for each qualified case in the HIV+ Tumor Characterization Project (HTMCP) study. The Tissue Source Site (TSS) should complete the form for qualified cases upon qualification notice from the Office of Cancer Genomics (OCG). Questions regarding this form should be directed to the Clinical Data Collection Operation & Database (CDCOD) or OCG.

Please note the following definitions for the "Unknown" and "Not Evaluated" answer options on this form.

Unknown: This answer option should only be selected if the TSS does not know this information after all efforts to obtain the data have been exhausted. If this answer option is selected for a question that is part of the HTMCP required data set, the TSS must complete a discrepancy note providing a reason why the answer is unknown.

Not Evaluated: This answer option should only be selected by the TSS if it is known that the information being requested cannot be obtained. This could be because the test in question was never performed on the patient or the TSS knows that the information requested was never disclosed.

Tissue	e Source Site (TSS):	TSS Identifier:	TSS Unique Patient Identifier:
Completed By (Interviewer Name in OpenClinica):			Completed Date:
# Data Element Entry Alternatives			Working Instructions
Gen	eral Information		
*1	Is this a prospective tissue	Yes	Indicate whether the TSS providing tissue is contracted for prospective tissue collection. If the submitted tissue was collected after the date the HTMCP contract was executed, the tissue has

*1	Is this a prospective tissue collection?	□ Yes □ No	Indicate whether the TSS providing tissue is contracted for prospective tissue collection. If the submitted tissue was collected after the date the HTMCP contract was executed, the tissue has been collected prospectively. 3088492					
*2	Is this a retrospective tissue collection?	□ Yes □ No	Indicate whether the TSS providing tissue is contracted for retrospective tissue collection. If the submitted tissue was collected prior to the date the HTMCP contract was executed, the tissue has been collected retrospectively. 3088528					
	Patient Information							
Dem	ographic Information							
*3	Date of Birth	//	Provide the date the patient was born. 2896950 (month), 2896952 (day), 2896954 (year) Note: The day of Birth is not required.					
*4	Gender	☐ Female ☐ Male	Provide the patient's gender using the provided categories. 2200604					
*5	Race (check all that apply)	□ American Indian or Alaska Native □ Asian □ White □ Black or African American □ Native Hawaiian or other Pacific Islander □ Not Evaluated □ Unknown	Provide the patient's race using the defined categories. 2192199 American Indian or Alaska Native: A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. Asian: A person having origins in any of the original peoples of the far East, Southeast Asia, or in the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. White: A person having origins in any of the original peoples of the four Europe, the Middle East, or North Africa. Black or African American: A person having origins in any of any of the black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African American." Native Hawaiian or other Pacific Islander: A person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. Not Evaluated: Not provided or available Unknown: Could not be determined or unsure					
6	Ethnicity	□ Not Hispanic or Latino □ Hispanic or Latino □ Not Evaluated □ Unknown	Provide the patient's ethnicity using the defined categories. 2192217 Not Hispanic or Latino: A person not meeting the definition of Hispanic or Latino. Hispanic or Latino: A person of Mexican, Puerto Rican, Cuban, Central or South American, or other Spanish culture or origin, regardless of race. Not Evaluated: Not provided or available Unknown: Could not be determined or unsure					
7	Height (at time of diagnosis)	(cm)	Provide the patient's height (centimeters) at the time the patient was diagnosed with the tumor submitted for HTMCP. 649					
8	Weight (at time of diagnosis)	(kg)	Provide the patient's weight (kilograms) at the time the patient was diagnosed with the tumor submitted for HTMCP. 651					
Surv	ival Information		<u>'</u>					
*9	Vital Status (at date of last contact)	☐ Living ☐ Deceased	Indicate whether the patient was living or deceased at the date of last contact.					

#	Data Element	Entry Alternatives	Working Instructions
π	Data Element	Entry Afternatives	5
†10	Date of Last Contact	//	If the patient is living, provide the date of last contact with the patient (as reported by the patient, medical provider, family member, or caregiver). 2897020 (month), 2897022 (day), 2897024 (year) Note: The day of Last Contact is not required.
*11	Date of Last Known Alive	//(month) (day) (year)	Indicate the last date the patient was known to be alive, regardless of whether the patient, medical provider, family member or caregiver was contacted. 2975722 (month), 2975724 (day), 2975726 (year) Note: The day of Last Known Alive is not required.
†12	Date of Death	//(gear)	If the patient is deceased, provide the date of death. 2897026, (month) 2897028 (day), 2897030 (year) Note: The day of Death is not required.
13	Cause of Death Only complete if patient is deceased.	☐ Cancer Related ☐ Non-Cancer Related ☐ Unknown ☐ Other (please specify)	Indicate the patient's cause of death. 2554674
14	Other Cause of Death Only complete if "other" is selected in #14.		If the patient's cause of death was not included in the provided list, specify the patient's cause of death. 2004150
Patie	nt Status (Regarding Submitted	d Tumor)	
*15	Did the patient receive neo-adjuvant therapy for the tumor submitted for HTMCP?	☐ Yes (exclusion criterion) ☐ No	Indicate whether the patient received treatment (radiation, pharmaceutical, or both) prior to the procurement of the sample submitted for HTMCP. 3382737 If the answer to this question is "yes", the submitted case is excluded.
*16	Tumor Status (at time of last contact or death)	☐ Tumor free ☐ With tumor ☐ Unknown Tumor Status	Indicate whether the patient was tumor/disease free (i.e. free of the malignancy that yielded the sample submitted for the HTMCP study) at the date of last contact or death. 2759550
Perfo	rmance Scores		
17	Performance Status Scale: Eastern Cooperative Oncology Group (ECOG) (At time of Diagnosis)	□ 0: Asymptomatic □ 1: Symptomatic, but fully ambulatory □ 2: Symptomatic, in bed less than 50% of day □ 3: Symptomatic, in bed more than 50% of day □ 4: Bed-ridden □ Unknown □ Not Evaluated	Provide the Eastern Cooperative Oncology Group (ECOG) performance status of the patient at the time of diagnosis. 88
18	Performance Status Score: Karnofsky Score (At time of Diagnosis)	 □ 100: Normal, no complaints, no evidence of disease □ 90: Able to carry on normal activity; minor signs or symptoms of disease □ 80: Normal activity with effort; some signs or symptoms of disease □ 70: Cares for self, unable to carry on normal activity or to do active work □ 60: Requires occasional assistance □ 50: Requires considerable assistance and frequent medical care □ 40: Disabled, requires special care and assistance □ 30: Severely disabled, hospitalization indicated. Death not imminent □ 20: Very sick, hospitalization □ 10: Moribund, fatal processes progressing rapidly □ 0: Dead □ Unknown □ Not Evaluated 	Provide the Karnofsky Score performance status of the patient at the time of diagnosis. 2003853
19	Tumor Response	☐ Progressive Disease ☐ Stable Disease ☐ Partial Response ☐ Complete Response	Indicate the patient's measure of success after their primary treatment including surgery and adjuvant therapies. 2786727
*20	Adjuvant (Post- Operative) Radiation Therapy	☐ Yes ☐ No ☐ Unknown	Indicate whether the patient had adjuvant/ post-operative radiation therapy <i>for the tumor submitted for HTMCP.</i> 2005312
*21	Adjuvant (Post- Operative) Pharmaceutical Therapy	☐ Yes ☐ No ☐ Unknown	Indicate whether the patient had adjuvant/ post-operative pharmaceutical therapy <i>for the tumor submitted for HTMCP</i> . 3397567
	Tobacco Smoking History	■ 1. Lifelang Non-Smoker	Indicate the nationt's history of tobacco smoking including their

#	Data Element	Entry Alternatives	Working Instructions
_#	Indicator (at time of diagnosis)	□ 2: Current Smoker □ 3: Current Reformed Smoker for > 15 years □ 4: Current Reformed Smoker for ≤15 years □ 5: Current Reformed Smoker (duration not specified) □ Smoking Status not Documented	smoking status at diagnosis using the defined categories. If the patient is or was a lifelong non-smoker, skip the additional smoking questions. 2181650
23	Age of Onset Tobacco History Indicator		Provide the age in years when the patient began smoking cigarettes. 2178045
24	Year of Quitting Tobacco Smoking	(YYYY)	Provide the year the patient quit smoking. 2228610
25	Number of Pack Years Smoked (at time of diagnosis)	pack years	Provide the number of pack years the patient smoked. This is calculated using the number of cigarettes smoked per day times the number of years smoked, divided by 20. For example, if the patient smoked 5 cigarettes per day times 10 years divided by 20, the patient would have 2.5 pack years (e.g. 5x10/20=2.5). 2955385
Pati	ent History of Disease		
HIV	Status		
*26	Is this patient HIV positive?	☐ Yes ☐ No ☐ Unknown	Indicate whether the patient is HIV positive. 2180464
†27	Date of HIV Diagnosis	/	Provide the date the patient was diagnosed with HIV. 3579640 (month), 3579644 (day), 3579643 (year) Note: The day of HIV Diagnosis is not required.
28	Nadir CD4 Counts	(cells/mm ³)	Provide the patient's Nadir CD4 counts, which are the lowest CD4 counts the patient has had. 2684395
†29	CD4 Counts at Diagnosis of the Submitted Malignancy	(cells/mm ³)	Provide the patient's CD4 Counts at the time the patient was diagnosed with the malignancy submitted for the HTMCP study. 2922654
†30	HIV RNA load at Diagnosis of Submitted Malignancy		Provide the HIV RNA load (also known as the "viral load") at the time the patient was diagnosed with the malignancy submitted for the HTMCP study. 2922674
31	Prior AIDS Defining Conditions	□ Candidiasis of bronchi, trachea or lungs □ Candidiasis, esophageal □ CMV other than liver, spleen or nodes, onset at age >1month □ CMV retinitis □ Coccidioidomycosis, disseminated or extrapulmonary □ Cryptococcosis, extrapulmonary □ Cryptosporidiosis, chronic intestinal □ Encephalopathy, HIV-related □ Herpes simplex: chronic ulcers (> 1 month's duration) or bronchitis, pneumonitis or esophagitis (onset at age > 1 month) □ Histoplasmosis, disseminated or extrapulmonary □ Isosporiasis, chronic intestinal (> 1 mon) □ Mycobacterium avium complex or Mycobacterium kansasii disseminated or extrapulmonary □ Mycobacterium tuberculosis of any site, pulmonary, disseminated or extrapulmonary □ Mycobacterium, other species or unidentified species, disseminated or extrapulmonary □ Nocardiosis	Prior to the malignancy submitted for the HTMCP study, provide any AIDS defining conditions 2679581

#	Data Element	Entry Alternatives			Working Instructions		
		☐ Pneumocystis jirovecii pneumonia ☐ Pneumonia, recurrent ☐ Progressive multifocal leukoencephalopathy ☐ Salmonella septicemia, recurrent ☐ Toxoplasmosis of the brain, onset at age			t il a, recurrent	tage	
		>1mont Wasting		ome, di	ue to HIV		
					Results	1	Using the list provided, indicate whether the patient had any co-
		Test	Pos	Neg	Inconclusive	Not Tested	infections by providing the results of each of the tests listed.
32	Co-Infections (serology data/viral load if	28. HBV				resteu	<u>2180456</u>
32	available)	29. HCV					<u>2695021</u>
	, , , , , ,	30. HPV 31. KSHV					<u>2230033</u> 3335773
		/HHV8					
†33	HAART Treatment Prior to Diagnosis of Submitted Malignancy	☐ Yes ☐ No ☐ Unknov	□Yes				Indicate whether the patient received Highly Active Antiretroviral Therapy (HAART) treatment prior to the diagnosis of the malignancy submitted for the HTMCP study. 3335156
†34	HAART Treatment at Time of Diagnosis of Submitted Malignancy	☐ Yes ☐ No ☐ Unknov	vn				Indicate whether the patient received Highly Active Antiretroviral Therapy (HAART) treatment at the time of the diagnosis of the malignancy submitted for the HTMCP study. 2922679
35	CDC HIV Risk Group	☐ Heteros ☐ IV drug ☐ Transfu	☐ Homosexual or bisexual contact ☐ Heterosexual contact ☐ IV drug user ☐ Transfusion recipient ☐ Hemophiliac				Indicate whether the patient has a history of any of the listed HIV Risk Groups as defined by the Center for Disease Control (CDC). 2542215
Prio	r Malignancies						
*36	Has this patient at any time in their life had a prior diagnosis of a malignant neoplasm?	☐ Yes (exclusion criterion)☐ No			n)		Indicate whether the patient was, at any time in their life, diagnosed with a malignancy prior to the diagnosis of the specimen submitted for HTMCP. 3382736 If the answer to this question is "yes", the submitted case is excluded. This exclusion does not apply if the patient only has a history of non-melanoma skin cancer, in situ carcinoma or Kaposi's Sarcoma.
	Type of Prior						If the patient has had a prior diagnosis of a malignant neoplasm,
37	Malignancies						provide the type of prior malignancy.
	Only complete if "yes" is selected in #37.						2718428
Prio	r Immunological Disease	— 51					
38	Patient History of Prior Immunological Disease	☐ Rheumatoid Arthritis ☐ Sjogren's Syndrome ☐ Systemic Lupus Erythematosus ☐ Crohn's Disease ☐ Ulcerative Colitis ☐ Hashimoto's Thyroiditis ☐ Other, please specify ☐ Unknown			ematosus		Indicate whether the patient has a history of any of the listed immunological diseases. 3233628
39	Other History of Prior Immunological Disease Only complete if "other" is selected in #39.				-		If the patient has a history of immunological disease and the disease is not listed in the previous question, provide the name of the disease(s). 3233629
40	Patient History of Prior Immunosuppressive Therapy for Immunological Disease	☐ Methoti ☐ Cycloph ☐ Azathio	iosphai	mide	☐ Anti-TNF th☐ None☐ Other☐ Unknown	nerapy	If the patient received immunosuppressive therapy for the immunological disease selected in the previous question, provide the type of immunosuppressive therapy given. 3233638
41	Other History of Prior Immunosuppressive Therapy for Immunological Disease				-		If the patient has a history of immunosuppressive therapy for immunological disease and the immunosuppressive therapy is not listed in the previous question, provide the name of the immunosuppressive therapy(s).

#	Data Element	Entry Alternatives	Working Instructions
	Only complete if "other" is selected in #41.	•	2873928
Prio	r Infectious Disease		
42	Patient History of Relevant Prior Infectious Disease	☐ Hepatitis B ☐ Other ☐ Hepatitis C ☐ Unknown ☐ H. Pylori	Indicate whether the patient has a history of any of the listed infectious disease. 3233642
43	Patient History of Other Relevant Infectious Disease Only complete if "other" is selected in #43.		If the patient has a history of relevant prior disease that was not included in the list, provide the infectious disease. 3233643
Path	ologic Information		
*44	Histological Subtype	□ Non-Small Cell Lung Cancer (NOS) □ Large cell carcinoma; Specify □ Large cell neuroendocrine carcinoma □ Small Cell Lung Cancer Squamous Cell Carcinoma □ Squamous Cell Carcinoma; NOS □ Squamous Cell Carcinoma; Keratinizing □ Squamous Cell Carcinoma; Non-keratinizing □ Small Cell Squamous Cell □ Basaloid Squamous Cell □ Basaloid Squamous Cell Adenocarcinoma □ Adenocarcinoma; NOS □ Bronchoalveolar carcinoma/AIS; non-mucinous □ Bronchoalveolar carcinoma/AIS; mucinous □ Minimally invasive adenocarcinoma □ Lepidic predominant adenocarcinoma □ Adenocarcinoma; Mixed Subtype; NOS □ Invasive mucinous adenocarcinoma □ Adenosquamous □ Special type; specify	Using the patient's final diagnostic pathology report, provide the most detailed histological subtype available. 3081934
†45	Other Histological Subtype		If the histological subtype is not included in the provided list, specify the histological subtype of the tumor that is being submitted. 3124492
*46	Organ of Origin	Lung	Using the patient's pathology/laboratory report, select the organ where the disease originated. 3427536
*47	Laterality	☐ Right ☐ Left ☐ Bilateral	Using the patient's pathology/laboratory report, select the laterality of the disease. Include all areas of invasion. 827
*48	Anatomic Organ Subdivision (Check all that apply)	□ Upper Lobe □ Middle Lobe (right only) □ Lower Lobe □ Bronchus □ Mediastinal □ Other (please specify)	Using the patient's pathology/laboratory report, select the anatomic organ subdivision(s) of the disease. Include all areas of invasion. 2008006
†49	Other Anatomic Organ Subdivision Only complete if "other" is selected in #48		If the anatomic organ subdivision was not included in the provided, indicate the anatomic organ subdivision of the disease. 2584114
Path	ologic Diagnosis and Surgic	cal Resection	
*50	Date of Initial Pathologic Diagnosis	/	Provide the date the patient was initially pathologically diagnosed with the malignancy submitted for HTMCP. This may or may not be the date of the surgical resection that yielded the tumor sample submitted for HTMCP. 2896956 (month), 2896958 (day), 2896960 (year)

#	Data Element	Entry Alternatives	Working Instructions
	2 4.04 2.0	☐ Fine Needle Aspiration Biopsy	Provide the method of the initial pathologic diagnosis.
			2757941
	34 d 1 CT (c) 1	☐ Incisional Biopsy	Depending on the method of initial pathologic diagnosis, this could
*51	Method of Initial	☐ Excisional Biopsy	be the same date provided for the previous question asking for the
31	Pathologic Diagnosis	☐ Surgical Resection	
		☐ Other (please specify)	pathologic diagnosis date.
		□ Unknown	
	Other Method of Initial		If the method of initial pathologic diagnosis is not included in the
			list above, provide the method used.
†52	Pathologic Diagnosis		2757948
	Only complete if "other" is selected in #51.		2737740
	Selected III #31.		Provide the date of the surgical resection that yielded the tumor
			sample submitted for HTMCP. Depending on the method of initial
=0	5	/ /	pathologic diagnosis, this could be the same date provided for the
53	Date of Surgical Resection	(month) (day) (year)	previous question asking for the pathologic diagnosis date.
		(monus) (uuy) (yeur)	3008197 (month), 3008195 (day), 3008199 (year)
		RX: Margins not assessed	Using the defined categories, indicate the patient's residual tumor
		☐ R0: Negative margins	margins after their final surgery.
54	Residual Tumor	☐ R1: Microscopic positive margins	<u>2608702</u>
51	Residual Famol	R2: Macroscopic positive margins	
		☐ Not Evaluated	
Lym	ph Node Status	I —	
	Were Lymph Nodes	☐ Yes	Indicate whether any lymph nodes were examined at the time of the
55	Examined at the Time of	□ No	primary resection.
	Primary Resection?	□ Unknown	<u>2200396</u>
	Number of Lymph Nodes		Provide the number of lymph nodes examined, if one or more
= .	Examined		lymph nodes were removed.
56	Only complete if "yes" is selected		3
	in #55.		
	Number of Lymph Nodes		Provide the number of lymph nodes positive through hematoxylin
	Positive by H&E light		and eosin (H&E) staining and light microscopy.
57			3086388
37	microscopy only		0000000
	Only complete if "yes" is selected in #55.		
	Number of Lymph Nodes		Provide the number of lymph nodes positive through keratin
			immunohistochemistry (IHC) staining.
58	Positive by IHC Keratin		3086383
36	Staining only		<u>3000303</u>
	Only complete if "yes" is selected in #55.		
	III #33.		Using the patient's pathology/laboratory report, provide the
		☐ Pelvic (external iliac, internal iliac, obturator)	location(s) of any positive lymph nodes.
	Pathologic Positive	Common iliac	
	Lymph Node Location(s)		<u>3151519</u>
59		☐ Paraaortic	
3,	(Check all that apply)	☐ Supraclavicular	
	Only complete if "yes" is selected in #55.	☐ Unknown	
	III #33.	□ Other, please specify	
		1	
	Other Positive Lymph		If the location of positive lymph nodes was not included in the list
60	Node		provided, please provide the location of positive lymph nodes.
60	Only complete if "yes" is selected		3151522
	in #55.		
AJCC	Staging		
	0 0	Clinical Pathologic	Using the patient's medical records, select the primary tumor
			category (T) used to determine the patient's final AJCC stage.
			<u>3440328</u> (clinical), <u>3045435</u> (pathologic)
		T1	Clinical and/or pathologic staging can be selected, but pathologic
		□ T1a □ T1a	staging is preferred.
†61	Primary Tumor (T)	□ T1b □ T1b	Stability is preferred.
.01	Tilliary rumor (1)		
		□ T2 □ T2 □ T2 □ T2a □ T2a	
		□ T2b □ T2b □ T3 □ T3	
		T4 T4	Heing the nationt's modical records color the nationt's regional
		Clinical Pathologic	Using the patient's medical records, select the patient's regional lymph node category (N) used to determine the patient's final AJCC
+(2	Regional Lymph Nodes	NX NX	
†62	(N)	□ NO □ NO	stage.
		□ N1 □ N1	3440330 (clinical), 3203106 (pathologic) Clinical and/or pathologic staging can be selected, but pathologic
1		□ N2 □ N2	Cimical and/or pathologic staging can be selected, but pathologic

#	Data Element	Entry Alternatives	Working Instructions
		□ N3 □ N3	staging is preferred.
		Clinical Pathologic	Using the patient's medical records, select the patient's distant metastasis category (M) used to determine the patient's final AJCC
		□ MX	stage.
†63	Distant Metastasis (M)		3440331 (clinical), 3045439 (pathologic)
		□ M1a □ M1a	Clinical and/or pathologic staging can be selected, but pathologic
		□ M1b □ M1b	staging is preferred.
		Clinical Pathologic	Using the patient's medical records, select the final AJCC stage.
		☐ Stage I ☐ Stage I	<u>3440332</u> (clinical), <u>3203222</u> (pathologic)
		☐ Stage IA ☐ Stage IA	Clinical and/or pathologic staging can be selected, but pathologic
		☐ Stage IB ☐ Stage IB ☐ Stage II ☐ Stage II	staging is preferred.
†64	Overall Stage	☐ Stage II ☐ Stage IIA	
"		☐ Stage IIB ☐ Stage IIB	
		☐ Stage III ☐ Stage III	
		☐ Stage IIIA ☐ Stage IIIA	
		☐ Stage IIIB ☐ Stage IIIB	
		☐ Stage IV ☐ Stage IV ☐ Stage IV ☐ 1st Edition (1978-1983)	Please select the AJCCC cancer staging edition used to determine
		□ 2 nd Edition (1984-1988)	the T, N, M, and stage provided.
		□ 3 rd Edition (1989-1992)	2722309
*65	AJCC Staging Edition Used	□ 4 th Edition (1993-1997)	
0.5	to Stage the Patient	□ 5 th Edition (1998-2002)	
		□ 6 th Edition (2003-2009)	
		☐ 7 th Edition (2010-present)	
Nov	, Tumor Event Informati		tumor event. If the patient did not have a new tumor event (or if
Nev	Tumor Event imormati		estion below, and the remainder of this section can be skipped.
		The 155 does not know) malcute this in the que	•
			Indicate whether the patient had a new tumor event (e.g. metastatic, recurrent, or new primary tumor) after initial
	New Tumor Event After	□Yes	treatment.
*i	Initial Treatment?	□No	<u>3121376</u>
		□ Unknown	If the patient did not have a new tumor event or if this is
			unknown, the remaining questions can be skipped.
		☐ Locoregional Recurrence	Indicate whether the patient's new tumor event was a
ii	Type of New Tumor Event	☐ Distant Metastasis	locoregional recurrence or a distant metastasis of the tissue submitted for HTMCP; or a new primary tumor.
		☐ New Primary Tumor	3119721
			Indicate the site of this new tumor event
	Anatomic Site of New	Bone Retroperitoneum	<u>3108271</u>
iii	Tumor Event	☐ Lung ☐ Lymph Node(s) ☐ Liver ☐ Other, specify	
		Liver Other, specify	
			If the site of the new tumor event is not included in the
iv	Other Site of New Tumor		provided list, describe the site of this new tumor event.
	Event		<u>3128033</u>
			If the patient had a new tumor event, provide the date of
		, ,	diagnosis for this new tumor event.
†V	Date of New Tumor Event	(month) (day) (year)	3104044 (Month), 3104042 (Day), 3104046 (Year)
		(month) (day)	
	Diagnostic Evidence of	☐ Biopsy w/Histologic Confirmation	Indicate the procedure or testing method used to diagnose
vi	Recurrence / Relapse	Convincing Imaging (i.e. CT, PET, MRI)	tumor recurrence or relapse.
	(check all that apply)	☐ Positive Biomarker(s)	<u>2786205</u>
	4.11		Using the patient's medical records, indicate whether the
vii	Additional Surgery for	☐ Yes ☐ Unknown	patient had surgery for the new metastatic tumor event in
	New Tumor Event	□ No	question. 3427611
	Additional Treatment of		Indicate whether the patient received radiation
viii	New Tumor Event	☐ Yes ☐ Unknown	treatment for this new tumor event.
V 111	Radiation Therapy	□ No □ Olikilowii	342761 <u>5</u>
	Additional Treatment of	-	Indicate whether the patient received
ix	New Tumor Event	☐ Yes ☐ Unknown	pharmaceutical treatment for this new tumor event.
	Pharmaceutical Therapy	□ No	<u>3427616</u>
Pati	ient Status		•

Enrollment Form	V1.39 093015
HTMCP – Lung	

#	Data Element	Entry Alternatives	Working Instructions
*66	Is This Patient Lost to Follow-up?	☐ Yes ☐ No	Indicate whether the patient is lost to follow-up as defined by the ACoS Commission on Cancer. This only includes cases where updated information has not been collected within the last 15 months. If the patient is lost to follow-up, the remaining questions may be left unanswered. 61333 If the patient is lost to follow-up or deceased at the time of enrollment, follow-up forms are not required.
	Principal Investigat	cor (Printed Name)	
	Principal Investiga	tor (Signature)	Date

 $I\ acknowledge\ that\ the\ above\ information\ provided\ by\ my\ institution\ is\ true\ and\ correct\ and\ has\ been\ quality\ controlled.$